한국동물위생학회지 (Korean Journal of Veterinary Service)

  • 제25권3호
  • /
  • Pages.309-314
  • /
  • 2002
  • /
  • 3022-7372(pISSN)
  • /
  • 2287-7630(eISSN)
한국동물위생학회 (The Korean Society of Veterinary Service)
권호 표지

마우스에서 Interleukin-2가 RD-995 종양세포에 미치는 항암효과

Effect of interleukin-2 on antitumor response against intraperitoneal RD-995 tumor in mice

  • 권오덕 (전북대학교 수의과대학)
  • 발행 : 2002.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Recombinant interleukin-2(IL-2) has demonstrated as an antineoplastic agent in mice and human, but the relatively low response rates observed in clinical trials. Therefore, the present study was undertaken in order to evaluate therapeutic activities of IL-2 for the establishment of therapeutic applications. At the onset of the experiment, normal C3H/HeN mice were injected with 5$\times$10$\^$6/ RD-995 tumor cells, murine ultraviolet radiation-induced fibrosarcoma, intraperitoneally. Beginning on day 6, experimental groups were treated with a 5-day course of IL-2(subcutaneous injection of 30,000 IU every 12 hours for 5 days). The result of this experiment revealed that body weight gradually decreased from 20th day in control mice. Subcutaneous IL-2 therapy prevented partially decrease body weight, and prolonged survival of mice compared with control group.

키워드

참고문헌

  1. 해리슨내과학편찬위원회. 1997. Harrison's 내과학, 서울. 도서출판 정담 : 1977-1993
  2. Rosenberg SA, Lotze MT, Mule JJ 1988. New approach to the immunotherapy of cancer using interleukin-2. Ann Int Med 108 : 853-864
  3. Whittington R, Faulds D. 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46 : 446-514
  4. Brandau S, Suttmann H, Flad HD, et al. 2000. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2-and BCG-activated effector cells. Cancer Immunol Immunother 49 : 369-376
  5. Dutcher JP, Logan T, Gordon M, et al. 2000. Phase II trial of interleukin 2, interferon alpha. and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 6 : 3442-3450
  6. Margolin KA. 2000. Interleukin-2 in the treatment of renal cancer. Semin Oncol 27 : 194-203
  7. Anderson PM, Sorenson MA. 1994. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 27 : 19-31
  8. Kripke ML. 1977. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37 : 1395-1400
  9. Samlowski WE, Yim CY, McGregor JR, et al. 1995. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL- 2 treatment of mice. J Immunother 18: 166- 178
  10. Papa MZ, Vetto JT, Ettinghausen SE, et al. 1986. Effect of corticosteroid on the antitumor actrvity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res 46: 5618-5623
  11. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 : 457
  12. Kalbfleisch JD, Prentice RL. 1980. The statistical analysis of failure time data. John Wiley & Sons. New York: 143
  13. Thomson A. 1991. Interleukin-2. In : The cytokine handbook. Academic Press. London : 83-102
  14. Lotze MT, Grimn EA. Mazumder A, et al. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41 : 4420-4425
  15. Mertelsmann R, Welte K. 1986. Human interleukin-2 molecular biology. physiology and clinical possibilities. Immunol 172 : 400-419
  16. Paul WE. 1993. T-cell derived cytokines and their receptors. In: Fundamental immunology, 3rd ed. Raven Press. New York : 763-800
  17. Blay JY, Favrot MC, Negrier S, et al. 1990. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50 : 2371-2374
  18. Cifone MG, D'Alo S, Parroni R, et al. 1999. Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production. Blood 93 : 3876-3884
  19. Gelmo BT, Palladino MA Jr, Jeffe HS, et al. 1988. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5864-5867
  20. Hibbs JB Jr, Taintor RR, Vavrin Z, et al. 1988. Nitric oxide. A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157 : 87-94
  21. Hibbs JB Jr, Westenfelder C, Taintor RR, et al. 1992. Evidence for cytokine inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy. J Clin Invest 89 : 867-877
  22. Jansson OT, Morcos E, Brundin L, et al. 1998. Nitric oxide synthase activity in human renal cell carcinoma. J Urol 160 : 556-560
  23. Jyothi MD, Khar A. 2000. Interleukin-2-induced nitric oxide synthase and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma. Scand J Immunol 52 : 148-155
  24. Kasid A, Director EP, Rosenberg SA. 1989. Induction of endogeneous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 143: 736-739
  25. Lee SG, Hea DS, Yoon SJ, et al. 2000. Effect of GM-CSF and IL-2 coexpression on the anti-tumor immune response. Anticancer Res 20 : 2681-2686
  26. Mier JW, Vachino G, Van Der Meer JWM, et al. 1988. Induction of circulating tumor necrosis factor(TNF-$\alpha$) as the mechanism for the febrile response to interleukin-2(IL-2) in cancer patients. J Clin Immunol 8 : 426-436
  27. Robak T. 1995. Biological properties and therapeutic use of interleukin 2(IL-2). Postepy Hig Med Dosw 49: 367-393
  28. Yim CY, Lee CW, Choi SM, et al. 1996. Effects of nitric oxide(NO) synthesis inhibition on antitumor responses during interleukin-2(IL-2) treatment of mice. Korean J Intern Med 11 : 93-100
  29. Boccoli G, Masciulli R, Ruggeri EM, et al. 1990. Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment. Cancer Res 50 : 5795-5800
  30. Yim CY, Bastian NR, Smith JC, et al. 1993. Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers. Cancer Res 55 : 5507-5511
  31. Kwon OD. 2000. Effect of interleukin-2 on antitumor response against subcutaneous Meth-A tumor in mice. Korean J Vet Clin Med 17: 305-310
  32. Kwon OD. 2001. Effect of interleukin-2 on antitumor response against ultraviolet radiation-induced fibrosarcoma in mice. J Vet Clin Med 18: 14-17
  33. Yim CY, McGregor JR, Kwon OD, et al. 1995. Nitric oxide synthesis contributes to IL-2-induced antitumor response against intraperitoneal Meth A tumor. J Immunol 155: 4382-4390